Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

Abstract Background Immune checkpoint inhibitors (ICI) either alone or in combination with chemotherapy have expanded our choice of agents for the palliative treatment of non-small cell lung cancer (NSCLC) patients. Unfortunately, not all patients will experience favorable response to treatment with...

Full description

Bibliographic Details
Main Authors: Wolfgang M. Brueckl, Joachim H. Ficker, Gloria Zeitler
Format: Article
Language:English
Published: BMC 2020-12-01
Series:BMC Cancer
Subjects:
Immunotherapy
Immune checkpoint inhibitor (ICI)
PD-L1 inhibitor
NSCLC
Prognostic
Predictive
Online Access:https://doi.org/10.1186/s12885-020-07690-8

Internet

https://doi.org/10.1186/s12885-020-07690-8

Similar Items